```json
{
"content": [
{
"type": "paragraph",
"content": "Noninvasive Prenatal Testing (NIPT) is a genetic screening method that analyzes fetal DNA in maternal blood to detect chromosomal abnormalities, offering a safer alternative to invasive procedures. As maternal health prioritizes risk reduction and early diagnosis, the NIPT market size is projected to expand significantly, driven by technological innovation and evolving healthcare policies. This market forecast spans 2021–2033, with 2026 as the anchor year, reflecting trends in diagnostic accuracy, patient adoption, and global accessibility."
},
{
"type": "paragraph",
"content": "The global NIPT market reached $3.8 billion in 2025, with a CAGR of 11.4% anticipated from 2026 to 2033. Key forces shaping the industry expansion include advancements in next-generation sequencing (NGS) technologies, regulatory approvals streamlining access, and increased insurance coverage. North America remains the largest region, while Asia-Pacific is the fastest-growing market due to rising awareness and urbanization. Strategic partnerships among diagnostics firms and digital health integration are further accelerating market dynamics."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Next-Generation Sequencing (NGS)", "Quantitative PCR (qPCR)", "Other Technologies"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[2200, 2450, 2750, 3000, 3250, 3550, 3900, 4250, 4600, 5000, 5400, 5800, 6200], // NGS
[800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400], // qPCR
[300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, 520, 540] // Other
]
}
}
]
}
```
